teva semaglutide pharmaceutical industries ltd. - Articles - Page 4 The peptide backbone is produced by yeast fermentation Semaglutide

Please note this article is not meant to be medical advice

GLP-1 action in the pancreas includes an increase in insulin secretion and synthesis, an increase in pancreatic -cell proliferation and -cell survival, and a decrease in glucagon release

Response variability between individuals often depends on genetic factors that influence GLP-1 receptor sensitivity and peptide metabolism

This gradual dose escalation minimises side effects such as nausea whilst allowing the body to adjust to the medication

Furthermore, powerful evidence has emerged to show that GIPR signaling can enhance GLP-1-induced weight loss (73)